Filtern
Dokumenttyp
Sprache
- Englisch (3)
Schlagworte
- Amino acid analysis (1)
- Antibody quantification (1)
- Azo macroinitiators (1)
- Cancer (1)
- Mass Spectroscopy (1)
- Metabolomics (1)
- Peptide analysis (1)
- Round robin test (1)
- Starch (1)
Organisationseinheit der BAM
MACC1 is a prognostic and predictive metastasis biomarker for more than 20 solid Cancer entities. However, its role in cancer metabolism is not sufficiently explored. Here, we report on how MACC1 impacts the use of glucose, glutamine, lactate, pyruvate and fatty acids and show the comprehensive analysis of MACC1-driven metabolic networks. We analyzed concentrationdependent changes in nutrient use, nutrient depletion, metabolic tracing employing 13C-labeled substrates, and in vivo studies. We found that MACC1 permits numerous effects on cancer
metabolism. Most of those effects increased nutrient uptake. Furthermore, MACC1 alters metabolic pathways by affecting metabolite production or turnover from metabolic substrates. MACC1 supports use of glucose, glutamine and pyruvate via their increased depletion or altered distribution within metabolic pathways. In summary, we demonstrate that MACC1 is an important regulator of metabolism in cancer cells.
The aim of this work was the synthesis of starch macroinitiators for cationic polymer grafted starches that: (i) are free of cationic homopolymer, and (ii) display a high degree of conversion of the cationic monomer. We show that this can be achieved by a free-radical polymerization reaction using the cationic monomer N-methacryloyloxyethyl-N,N-dimethyl-N-benzylammonium chloride (MADAM-BQ) and a new starch-based macroazoinitiator. For this purpose, the acid chloride of 4-tert-butylazo-4-cyanovaleric acid was synthesized and bound covalently to starch (predominantly in the C6 position) to form a nonsymmetrically substituted macroinitiator that was used to polymerize MADAM-BQ in aqueous media. Essentially no MADAM-BQ homopolymer was formed. The initiator decomposes thermally to starch radicals of high reactivity and low-molar mass radicals that do not initiate polymerization. The reason for the different reactivities of the radicals is presumably due to the nonsymmetric constitution of the starch-bound azo groups. The graft polymerization of MADAM-BQ in aqueous solution performs according to an ideal overall kinetic. The structure of the synthesized starch-graft-poly(MADAM-BQ) products is similar to that of block copolymers because of the low radical efficiency of the starch initiators in aqueous solution. Especially, starch substrates with a higher content of azo groups did not lead to graft products with shorter graft distances because the state of solution of these macroinitiators becomes worse and aggregation occurs with an increasing degree of substitution.
Under the auspices of the Protein Analysis Working Group (PAWG) of the Comité Consultatif pour la Quantité de Matière (CCQM) a pilot study, CCQM-P216, was coordinated by the Chinese National Institute of Metrology (NIM), National Research Council of Canada (NRC) and the Bureau International des Poids et Mesures (BIPM). Eleven Metrology Institutes or Designated Institutes and the BIPM participated in the first phase of the pilot study (Part 1). The purpose of this pilot study was to develop measurement capabilities for larger proteins using a recombinant humanized IgG monoclonal antibody against Spike glycoprotein of SARS-CoV-2 (Anti-S IgG mAb) in solution. The first phase of the study was designed to employ established methods that had been previously studies by the CCQM Protein Analysis Working Group, involving the digestion of protein down to the peptide or amino acid level. The global coronavirus pandemic has also led to increased focus on antibody quantitation methods. IgG are among the immunoglobulins produced by the immune system to provide protection against SARS-CoV-2. Anti-SARS-CoV-2 IgG can therefore be detected in samples from affected patients. Antibody tests can show whether a person has been exposed to the SARS-CoV-2, and whether or not they potentially show lasting immunity to the disease. With the constant spread of the virus and the high pressure of re-opening economies, antibody testing plays a critical role in the fight against COVID-19 by helping healthcare professionals to identify individuals who have developed an immune response, either via vaccination or exposure to the virus. Many countries have launched large-scale antibody testing for COVID-19. The development of measurement standards for the antibody detection of SARS-CoV-2 is critically important to deal with the challenges of the COVID-19 pandemic. In this study, the SARS-CoV-2 monoclonal antibody is being used as a model system to build capacity in methods that can be used in antibody quantification. Amino acid reference values with corresponding expanded uncertainty of 36.10 ± 1.55 mg/kg, 38.75 ± 1.45 mg/kg, 18.46 ± 0.78 mg/kg, 16.20 ± 0.67 mg/kg and 30.61 ± 1.30 mg/kg have been established for leucine, valine, phenylalanine, isoleucine and proline, respectively. Agreement between nearly all laboratories was achieved for the amino acid analysis within 2 to 2.5 %, with one participant achieving markedly higher results due to a technical issue found in their procedure; this result was thus excluded from the reference value calculations. The relatively good agreement within a laboratory between different amino acids was not dissimilar to previous results for peptides or small proteins, indicating that factors such as hydrolysis conditions and calibration procedures could be the largest sources of variability. Peptide reference values with corresponding expanded uncertainty of 4.99 ± 0.28 mg/kg and 6.83 ± 0.65 mg/kg have been established for ALPAPIEK and GPSVFPLAPSSK, respectively. Not surprisingly due to prior knowledge from previous studies on peptide quantitation, agreement between laboratories for the peptide-based analysis was slightly poorer at 3 to 5 %, with one laboratory's result excluded for the peptide GPSVFPLAPSSK. Again, this level of agreement was not significantly poorer than that achieved in previous studies with smaller or less complex proteins. To reach the main text of this paper, click on Final Report.